Filing Details

Accession Number:
0001104659-14-057229
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-06 10:03:32
Reporting Period:
2014-08-05
Filing Date:
2014-08-06
Accepted Time:
2014-08-06 09:03:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1267813 Marinus Pharmaceuticals Inc MRNS Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1400308 M Stephen Bloch C/O Marinus Pharmaceuticals, Inc.
142 Temple St., Suite 205
Westport CT 06880
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-08-05 1,836,398 $0.00 1,836,398 No 4 C Indirect See Footnote
Common Stock Acquisiton 2014-08-05 625,000 $8.00 2,461,398 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2014-08-05 4,742,516 $0.00 729,618 $0.00
Common Stock Series B Preferred Stock Disposition 2014-08-05 3,838,214 $0.00 590,494 $0.00
Common Stock Series C Preferred Stock Disposition 2014-08-05 3,355,859 $0.00 516,286 $0.00
Common Stock Warrants to Purchase Series B Preferred Stock Disposition 2014-08-05 959,553 $10.86 147,624 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 J Indirect
Footnotes
  1. Upon the closing of Issuer's initial public offering on August 5, 2014, the preferred stock, which has no expiration date and convertible at any time at the option of the holder, automatically converted, at a conversion ratio of one share of Common Stock for every 6.5 shares of preferred stock, for no additional consideration.
  2. The securities are held directly by Canaan VII L.P. Dr. Bloch disclaims beneficial ownership over the securities owned by Canaan VII L.P., and this report shall not be deemed an admission that such reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in Canaan Partners VII LLC, the general partner of Canaan VII L.P.
  3. This warrant was immediately exercisable. Upon the closing of Issuer's public offering, the warrant was cancelled automatically and for no value in accordance with its terms as it was out-of-the-money.